Biggest changeThe following table sets forth our results of operations for the periods indicated: Year Ended December 31, 2024 2023 2024 2023 (In thousands) (As a percentage of revenue) Product sales $ 42,203 $ 53,123 84 % 83 % Licensing, royalty, patent, and other revenue 8,199 10,642 16 17 Total revenue 50,402 63,765 100 100 Cost of product sales 22,812 24,693 45 39 Cost of licensing, royalty, patent, and other revenue 1,464 1,827 3 3 Total cost of sales 24,276 26,520 48 42 Gross profit 26,126 37,245 52 58 Operating expenses: Research and development 13,686 11,776 27 19 General and administrative 14,141 14,296 28 22 Sales and marketing 5,390 5,288 11 8 Total operating expenses 33,217 31,360 66 49 (Loss) income from operations (7,091) 5,885 (14) 9 Interest expense — (63) — — Other income, net 7,832 3,214 16 5 Net income before income taxes 741 9,036 2 14 Income tax benefit 40 16 — — Net income $ 781 $ 9,052 2 % 14 % Comparison of the Years Ended December 31, 2024 and 2023 Revenue We generated 79% and 78% of our revenue from products sold through distributors for the years ended December 31, 2024 and 2023, respectively. 28 Table of Contents We maintain a direct selling relationship, for strategic purposes, with several key customer accounts.
Biggest changeResults of Operations Below are factors we want to highlight for understanding our 2025 annual results and year-over-year comparison with proper historical perspective: • Our commitment to improving our manufacturing excellence enabled us to drive yield improvements within our internal and external foundries network to sustain existing product margins. 28 Table of Contents The following table sets forth our results of operations for the periods indicated: Year Ended December 31, 2025 2024 2025 2024 (In thousands) (As a percentage of revenue) Product sales $ 48,292 $ 42,203 87 % 84 % Licensing, royalty, patent, engineering services and other revenue 6,910 8,199 13 16 Total revenue 55,202 50,402 100 100 Cost of product sales 25,938 22,812 47 45 Cost of licensing, royalty, patent, engineering services and other revenue 1,022 1,464 2 3 Total cost of sales 26,960 24,276 49 48 Gross profit 28,242 26,126 51 52 Operating expenses: Research and development 14,085 13,686 26 27 General and administrative 14,552 14,141 26 28 Sales and marketing 6,113 5,390 11 11 Total operating expenses 34,750 33,217 63 66 Loss from operations (6,508) (7,091) (12) (14) Interest income 1,646 1,766 3 3 Other income, net 4,405 6,066 8 13 Net (loss) income before income taxes (457) 741 (1) 2 Income tax (expense) benefit (129) 40 — — Net (loss) income and comprehensive (loss) income $ (586) $ 781 (1) % 2 % Comparison of the Years Ended December 31, 2025 and 2024 Revenue We generated 75% and 79% of our revenue from products sold through distributors for the years ended December 31, 2025 and 2024, respectively.
Design wins . To continue to grow our revenue, we must continue to achieve design wins for our MRAM products. We consider a design win to occur when an OEM or contract manufacturer notifies us that it has qualified one of our products as a component in a product or system for production.
To continue to grow our revenue, we must continue to achieve design wins for our MRAM products. We consider a design win to occur when an OEM or contract manufacturer notifies us that it has qualified one of our products as a component in a product or system for production.
For sales directly to OEMs, ODMs and CMs, we recognize revenue when the OEM, ODM or CM obtains control of the product, which occurs at a point in time, generally upon shipment to the customer. 32 Table of Contents From time to time, we may provide distributors with price adjustments subsequent to the delivery of product to them and such amounts are dependent on the end customer and product sales price.
For sales directly to OEMs, ODMs and CMs, we recognize revenue when the OEM, ODM or CM obtains control of the product, which occurs at a point in time, generally upon shipment to the customer. 33 Table of Contents From time to time, we may provide distributors with price adjustments subsequent to the delivery of product to them and such amounts are dependent on the end customer and product sales price.
Upon the transfer of control, generally at shipment, we record a trade receivable for the selling price as there is a legally enforceable obligation of the distributor to pay for the product delivered, an allowance is recorded for the estimated discount that will be provided to the distributor, and the net of these amounts is recorded as revenue on the statements of income and comprehensive income.
Upon the transfer of control, generally at shipment, we record a trade receivable for the selling price as there is a legally enforceable obligation of the distributor to pay for the product delivered, an allowance is recorded for the estimated discount that will be provided to the distributor, and the net of these amounts is recorded as revenue on the statements of operations and comprehensive (loss) income.
The change in our net operating assets and liabilities was primarily due to an increase in contract obligations of $2.0 million due to contracts the Company entered into in the third quarter of 2024, an increase in accounts receivable of $0.2 million due to timing of cash receipts for outstanding balances, an increase in inventory of $0.7 million to meet anticipated production volumes, an increase in prepaid and other current assets of $0.3 million, an increase in other assets of $0.5 million, a decrease in accounts payable of $0.4 million, a decrease in accrued liabilities of $1.9 million, and a decrease in deferred revenue of $0.3 million.
The change in our net operating assets and liabilities was primarily due to an increase in 32 Table of Contents contract obligations of $2.0 million due to contracts the Company entered into in the third quarter of 2024, an increase in accounts receivable of $0.2 million due to timing of cash receipts for outstanding balances, an increase in inventory of $0.7 million to meet anticipated production volumes, an increase in prepaid and other current assets of $0.3 million , an increase in other assets of $0.5 million , a decrease in accounts payable of $0.4 million , a decrease in accrued liabilities of $1.9 million , and a decrease in deferred revenue of $0.3 million .
Cash Flows from Financing Activities During the year ended December 31, 2024, cash provided by financing activities was $1.1 million, which consisted of proceeds from stock option exercises and purchases of shares under our employee stock purchase plan.
Cash Flows from Financing Activities During the year ended December 31, 2025, cash provided by financing activities was $1.1 million, which consisted of proceeds from stock option exercises and purchases of shares under our employee stock purchase plan.
We base our estimates on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources.
We base our estimates on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
Additionally, we monitor and project cash flow to determine our sources and uses for working capital to fund our operations. We also monitor Adjusted EBITDA, a non-GAAP financial measure, and design wins. We define Adjusted EBITDA as net income or loss adjusted for interest expense, taxes, depreciation and amortization, stock-based compensation expense, and restructuring costs, if any. Adjusted EBITDA.
Additionally, we monitor and project cash flow to determine our sources and uses for working capital to fund our operations. We also monitor Adjusted net income, a non-GAAP financial measure, and design wins. We define Adjusted net income as net income adjusted for stock-based compensation expense. Adjusted net income .
Cash Flows The following table summarizes our cash flows for the periods indicated (in thousands): Year Ended December 31, 2024 2023 (In thousands) Cash provided by operating activities $ 7,099 $ 13,128 Cash used in investing activities (3,060) (1,385) Cash provided by (used in) financing activities 1,112 (1,592) Cash Flows from Operating Activities During the year ended December 31, 2024, cash provided by operating activities was $7.1 million, which consisted of net income of $0.8 million, non-cash charges of $8.4 million and changes in net operating assets and liabilities of $2.1 million.
Cash Flows The following table summarizes our cash flows for the periods indicated (in thousands): Year Ended December 31, 2025 2024 (In thousands) Cash provided by operating activities $ 9,960 $ 7,099 Cash used in investing activities (8,674) (3,060) Cash provided by financing activities 1,067 1,112 Cash Flows from Operating Activities During the year ended December 31, 2025, cash provided by operating activities was $10.0 million , which consisted of net loss of $0.6 million , non-cash charges of $9.0 million and changes in net operating assets and liabilities of $1.6 million .
We record inventory write-downs for the valuation of inventory when required based on our analyses and any write-downs result in a new cost basis for the affected item. Recent Accounting Pronouncements See Note 2 in the accompanying Notes to Financial Statements in Part II, Item 8 of this Annual Report on Form 10-K for more information about recent accounting pronouncements, the timing of their adoption, and our assessment, to the extent we have made one yet, of their potential impact on our financial condition of results of operations.
Recent Accounting Pronouncements See Note 2 in the accompanying Notes to Financial Statements in Part II, Item 8 of this Annual Report on Form 10-K for more information about recent accounting pronouncements, the timing of their adoption, and our assessment, to the extent we have made one yet, of their potential impact on our financial condition of results of operations.
Research and development expenses increased by $1.9 million, or 16.2%, from $11.8 million during the year ended December 31, 2023, to $13.7 million during the year ended December 31, 2024.
Research and development expenses increased by $0.4 million, or 2.9%, from $13.7 million during the year ended December 31, 2024, to $14.1 million during the year ended December 31, 2025.
Our future capital requirements will depend on many factors, including, among other things, our growth rate, the timing and extent of our spending to support research and development activities, the timing and cost of establishing additional sales and marketing capabilities, and the introduction of new products. Additionally, see “Credit Facilities” below for information regarding our debt financing.
Our long-term capital requirements will depend on many factors, including, among other things, our growth rate, the timing and extent of our spending to support our current and future manufacturing requirements, research and development activities, the timing and cost of establishing additional sales and marketing capabilities, and the introduction of new products.
Accordingly, we determined the licenses were not distinct within the context of the contract and combined the license with other performance obligations. As a result, we are recognizing revenue related to the performance obligations over time using the input method based on costs incurred to date relative to the total expected costs of the contract over the performance obligation period. 33 Table of Contents Inventory We record inventories at the lower of cost, determined on a first-in, first-out basis or net realizable value.
Accordingly, we determined the licenses were not distinct within the context of the contract and combined the license with other performance obligations. As a result, we are recognizing revenue related to the performance obligations over time using the input method based on costs incurred to date relative to the total expected costs of the contract over the performance obligation period.
We applied a five-step approach in determining the amount and timing of revenue to be recognized: (1) identifying the contract with a customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price to the performance obligations in the contract; and (5) recognizing revenue when the performance obligation is satisfied. We concluded these contractual arrangements represent one arrangement and evaluated our promises to the customer and whether the performance obligations granted under the arrangement were distinct.
We applied a five-step approach in determining the amount and timing of revenue to be recognized: (1) identifying the contract with a customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price to the performance obligations in the contract; and (5) recognizing revenue when the performance obligation is satisfied.
During the year ended December 31, 2023, cash provided by operating activities was $13.1 million, which consisted of net income of $9.1 million , non-cash charges of $6.4 million and changes in net operating assets and liabilities of $2.3 million.
During the year ended December 31, 2024, cash provided by operating activities was $7.1 million, which consisted of net income of $0.8 million , non-cash charges of $8.4 million and changes in net operating assets and liabilities of $2.1 million . The non-cash charges primarily consisted of stock-based compensation of $6.7 million and depreciation and amortization of $1.7 million .
The non-cash charges primarily consisted of stock-based compensation of $6.7 million and depreciation and amortization of $1.7 million.
The non-cash charges primarily consisted of stock-based compensation of $5.8 million and depreciation and amortization of $3.2 million .
Interest Expense Year Ended December 31, Change 2024 2023 Amount % (Dollars in thousands) Interest expense $ — $ 63 $ (63) (100.0) % Interest expense decreased by $0.1 million, or 100.0%, from $0.1 million during the year ended December 31, 2023, to zero during the year ended December 31, 2024.
Interest Income Year Ended December 31, Change 2025 2024 Amount % (Dollars in thousands) Interest income $ 1,646 $ 1,766 $ (120) (6.8) % Interest income decreased by $0.1 million, or 6.8%, from $1.8 million during the year ended December 31, 2024, to $1.6 million during the year ended December 31, 2025.
During the year ended December 31, 2023, cash used in investing activities was $1.4 million, which consisted of capital expenditures primarily for the purchase of manufacturing equipment offset by a nominal amount in proceeds received on the sale of property and equipment.
During the year ended December 31, 2024, cash used in investing activities was $3.1 million, which consisted of capital expenditures primarily for the purchase of manufacturing equipment and purchased software.
Cost of Sales and Gross Margin Year Ended December 31, Change 2024 2023 Amount % (Dollars in thousands) Cost of sales $ 22,812 $ 24,693 $ (1,881) (7.6) % Cost of licensing, royalty, patent, and other revenue 1,464 1,827 (363) (19.9) % Total cost of sales $ 24,276 $ 26,520 $ (2,244) (8.5) % Gross margin 51.8 % 58.4 % * * Cost of product sales decreased by $1.9 million, or 7.6%, from $24.7 million during the year ended December 31, 2023, to $22.8 million during the year ended December 31, 2024.
Cost of Sales and Gross Margin Year Ended December 31, Change 2025 2024 Amount % (Dollars in thousands) Cost of sales $ 25,938 $ 22,812 $ 3,126 13.7 % Cost of licensing, royalty, patent, engineering services and other revenue 1,022 1,464 (442) (30.2) % Total cost of sales $ 26,960 $ 24,276 $ 2,684 11.1 % Gross margin 51.2 % 51.8 % * * Cost of product sales increased by $3.1 million, or 13.7%, from $22.8 million during the year ended December 31, 2024, to $25.9 million during the year ended December 31, 2025.
Sales and marketing expenses increased by $0.1 million, or 1.9%, from $5.3 million during the year ended December 31, 2023, to $5.4 million during the year ended December 31, 2024. The change was primarily due to an increase in headcount and contract labor, partially offset by lower variable compensation costs.
Sales and marketing expenses increased by $0.7 million, or 13.4%, from $5.4 million during the year ended December 31, 2024, to $6.1 million during the year ended December 31, 2025. The increase is sales and marketing expenses relates primarily to higher compensation costs and contract labor.
We write down inventory for estimated excess or obsolete inventory equal to the difference between cost and estimated net realizable value. Inventory write downs establish a new cost basis for inventory and charges are not subsequently reversed even if circumstances subsequently indicate that increased carrying amounts are recoverable.
Inventory write downs establish a new cost basis for inventory and charges are not subsequently reversed even if 34 Table of Contents circumstances subsequently indicate that increased carrying amounts are recoverable.
Our revenue by region for the periods indicated was as follows (in thousands): Year Ended December 31, 2024 2023 APAC $ 28,688 $ 33,096 North America 10,710 15,922 EMEA 11,004 14,747 Total revenue $ 50,402 $ 63,765 Year Ended December 31, Change 2024 2023 Amount % (Dollars in thousands) Product sales $ 42,203 $ 53,123 $ (10,920) (20.6) % Licensing, royalty, patent, and other revenue 8,199 10,642 (2,443) (23.0) % Total revenue $ 50,402 $ 63,765 $ (13,363) (21.0) % Total revenue decreased by $13.4 million, or 21.0%, from $63.8 million during the year ended December 31, 2023, to $50.4 million during the year ended December 31, 2024.
Our revenue by region for the periods indicated was as follows (in thousands): Year Ended December 31, 2025 2024 APAC $ 34,527 $ 28,688 North America 10,890 10,710 EMEA 9,785 11,004 Total revenue $ 55,202 $ 50,402 29 Table of Contents Year Ended December 31, Change 2025 2024 Amount % (Dollars in thousands) Product sales $ 48,292 $ 42,203 $ 6,089 14.4 % Licensing, royalty, patent, engineering services and other revenue 6,910 8,199 (1,289) (15.7) % Total revenue $ 55,202 $ 50,402 $ 4,800 9.5 % Total revenue increased by $4.8 million, or 9.5%, from $50.4 million during the year ended December 31, 2024, to $55.2 million during the year ended December 31, 2025.
The change was due to a decrease in licensing costs related to labor and materials associated with the progression of our RAD-Hard projects. Our gross margin decreased from 58.4% during the year ended December 31, 2023, to 51.8% during the year ended December 31, 2024.
Cost of licensing, royalty, patent, engineering services and other revenue decreased by $0.4 million, or 30.2%, from $1.5 million during the year ended December 31, 2024, to $1.0 million during the year ended December 31, 2025. The decrease was primarily due to a decrease in licensing costs related to labor and materials associated with the progression of our RAD-Hard projects.
We have organized our sales team and representatives into three primary regions: Asia-Pacific (APAC); North America; and Europe, Middle East and Africa (EMEA). We recognize revenue by geography based on the region in which our products are sold, and not to where the end products in which they are assembled are shipped.
We recognize revenue by geography based on the region in which our products are sold, and not to where the end products in which they are assembled are shipped.
We believe our cash and cash equivalents are sufficient to meet our anticipated capital requirements in the next 12 months.
Liquidity and Capital Resources As of December 31, 2025, we had $44.5 million of cash and cash equivalents, compared to $42.1 million as of December 31, 2024. We believe our cash and cash equivalents are sufficient to meet our anticipated capital requirements in the next 12 months.
General and administrative expenses decreased by $0.2 million, or 1.1%, from $14.3 million during the year ended December 31, 2023, to $14.1 million during the year ended December 31, 2024.
General and administrative expenses increased by $0.4 million, or 2.9%, from $14.1 million during the year ended December 31, 2024, to $14.6 million during the year ended December 31, 2025. The increase is primarily due to one-time professional service fees.
The change was primarily due to the development and enhancement of our new Extended Serial Peripheral Interface (xSPI) family of STT-MRAM products, which offer high-performance, multiple I/O, SPI-compatibility and feature a high-speed, low pin count SPI compatible interface, and increases in share-based compensation. Year Ended December 31, Change 2024 2023 Amount % (Dollars in thousands) General and administrative $ 14,141 $ 14,296 $ (155) (1.1) % General and administrative as a % of revenue 28 % 22 % General and Administrative Expenses.
Research and development expenses relate primarily to the development and enhancement of our new Extended Serial Peripheral Interface (xSPI) family of STT-MRAM products, which offer high-performance, multiple I/O, SPI-compatibility and feature a high-speed, low pin count SPI compatible interface.
The change in our net operating assets and liabilities was primarily due to an increase in accounts receivable of $0.9 million due to timing of cash receipts for outstanding balances, an increase in inventory of $1.7 million to meet anticipated production volumes, an increase in prepaid and other current assets of $0.4 million, an 31 Table of Contents increase in other assets of $0.2 million, an increase in accounts payable of $0.5 million, an increase in accrued liabilities of $0.8 million, and a decrease in deferred revenue of $0.5 million. Cash Flows from Investing Activities During the year ended December 31, 2024, cash used in investing activities was $3.1 million, which consisted of capital expenditures primarily for the purchase of manufacturing equipment and purchased software.
The change in our net operating assets and liabilities was primarily due to a decrease in accounts receivable of $3.6 million due to timing of cash receipts for outstanding balances, an increase in accrued liabilities of $0.8 million, a decrease in other assets of $0.4 million , an increase in long-term income tax liability of $0.1 million, offset by an increase in inventory of $1.6 million to meet anticipated production volumes, a decrease in accounts payable of $0.5 million, a decrease in contract obligations of $0.6 million, and an increase in prepaid and other current assets of $0.6 million .
Accordingly, we believe that Adjusted EBITDA provides useful information for investors in understanding and evaluating our operating results in the same manner as our management and our board of directors. Adjusted EBITDA is a non-GAAP financial measure and should be considered in addition to, not as superior to, or as a substitute for, net income reported in accordance with GAAP.
As such, we believe Adjusted net income provides meaningful insight for investors into our financial performance, consistent with how our management team and board view and analyze our results. Adjusted net income is a non-GAAP financial measure and should be considered alongside, but not as a replacement for or superior to, net income as reported in accordance with GAAP.
We recognize revenue net of allowances for returns and price concessions, and any taxes imposed on revenue transactions, which are subsequently remitted to governmental authorities.
Revenue Recognition We recognize revenue when a customer obtains control of the promised products or services, in an amount that reflects the consideration we expect to receive in exchange for those products or services. We recognize revenue net of allowances for returns and price concessions, and any taxes imposed on revenue transactions, which are subsequently remitted to governmental authorities.
The change was primarily driven by a reduction in professional services. Year Ended December 31, Change 2024 2023 Amount % (Dollars in thousands) Sales and marketing $ 5,390 $ 5,288 $ 102 1.9 % Sales and marketing as a % of revenue 11 % 8 % Sales and Marketing Expenses.
Year Ended December 31, Change 2025 2024 Amount % (Dollars in thousands) Sales and marketing $ 6,113 $ 5,390 $ 723 13.4 % Sales and marketing as a % of revenue 11 % 11 % Sales and Marketing Expenses .
The decrease was primarily due to a decrease in product sales of $10.9 million due to timing of customer demand. Licensing, royalty, patent, and other revenue is a highly variable revenue item characterized by a small number of transactions annually with revenue based on size and terms of each transaction.
Licensing, royalty, patent, engineering services and other revenue is a highly variable revenue item characterized by a small number of transactions annually with revenue based on size and terms of each transaction. We estimate royalty revenue earned throughout the year, with an annual adjustment recognized for actual sales in the first quarter of each fiscal year.
During the year ended December 31, 2023, cash used in financing activities was $1.6 million, which primarily consisted of $2.8 million of payments to pay off our 2019 Credit Facility offset by $1.2 million in proceeds from stock option exercises and purchases of shares under our employee stock purchase plan.
During the year ended December 31, 2024, cash used in financing activities was $1.1 million, which consisted of proceeds from stock option exercises and purchases of shares under our employee stock purchase plan. Critical Accounting Policies and Significant Judgments and Estimates Our financial statements have been prepared in accordance with U.S. GAAP.
The decrease was primarily due to the progression of our contractual agreements with customers for the development of RAD-Hard products, along with the conclusion of a contractual arrangement with a customer for the development of reliability models for strategic radiation hardened toggle MRAM. There were no patent sales during the year ended December 31, 2024.
Licensing, royalty, patent, engineering services and other revenue decreased by $1.3 million, from $8.2 million during the year ended December 31, 2024, to $6.9 million during the year ended December 31, 2025. The decrease was primarily due to the conclusion of a contractual arrangement with a customer for the development of reliability models for strategic radiation hardened toggle MRAM.
Personnel-related expenses, including salaries, benefits, bonuses, and stock-based compensation, are among the most significant component of each of our operating expense categories. Year Ended December 31, Change 2024 2023 Amount % (Dollars in thousands) Research and development $ 13,686 $ 11,776 $ 1,910 16.2 % Research and development as a % of revenue 27 % 19 % Research and Development Expenses .
Personnel-related expenses, including salaries, benefits, bonuses, and stock-based compensation, are among the most significant component of each of our operating expense categories.
Our management and board of directors use Adjusted EBITDA to understand and evaluate our operating performance and trends, to prepare and approve our annual budget and to develop short-term and long-term operating and financing plans.
Our management and board of directors use Adjusted net income to assess and evaluate our overall performance and financial trends, inform the annual budgeting process, and guide both short-term and long-term operational and strategic planning.
The following table presents a reconciliation of net income, the most directly comparable GAAP measure, to Adjusted EBITDA for the periods indicated: Year Ended December 31, 2024 2023 (in thousands) Adjusted EBITDA reconciliation: Net income $ 781 $ 9,052 Depreciation and amortization 1,731 1,205 Stock-based compensation expense 6,713 5,005 Interest expense — 63 Income tax benefit (40) (16) Adjusted EBITDA $ 9,185 $ 15,309 Our Adjusted EBITDA for the year ended December 31, 2023 includes a one-time employee retention tax credit received of $2.0 million in the second quarter of 2023.
The following table provides a reconciliation of net income, the most directly comparable GAAP measure, to Adjusted net income for the periods presented: Year Ended December 31, 2025 2024 (in thousands) Adjusted Net (Loss) Income reconciliation: Net (loss) income $ (586) $ 781 Stock-based compensation expense 5,776 6,713 Adjusted Net (Loss) Income $ 5,190 $ 7,494 Design wins .
Our gross margin decreased as a result of a shift in product mix, a decrease in FAB loadings, and a decrease in licensing revenue partially offset by increased yields on our toggle products. 29 Table of Contents Operating Expenses Our operating expenses consist of research and development, general and administrative and sales and marketing expenses.
Gross margin decreased from 51.8% during the year ended December 31, 2024, to 51.2% during the year ended December 31, 2025. Gross margin slightly decreased as a result of the different revenue mix. 30 Table of Contents Operating Expenses Our operating expenses consist of research and development, general and administrative and sales and marketing expenses.
The change was due to having no outstanding balance under our 2019 Credit Facility as we paid off the outstanding balance in full in March 2023, resulting in no interest incurred during 2024 after the outstanding balance was paid in full. 30 Table of Contents Other Income, Net Year Ended December 31, Change 2024 2023 Amount % (Dollars in thousands) Other income, net $ 7,832 $ 3,214 $ 4,618 143.7 % Other income, net increased by $4.6 million, from $3.2 million during the year ended December 31, 2023, to $7.8 million during the year ended December 31, 2024.
The decrease is primarily due to the decrease in interest rates. 31 Table of Contents Other Income, Net Year Ended December 31, Change 2025 2024 Amount % (Dollars in thousands) Other income, net $ 4,405 $ 6,066 $ (1,661) (27.4) % Other income, net decreased by $1.7 million, from $6.1 million during the year ended December 31, 2024, to $4.4 million during the year ended December 31, 2025.
New design wins in each successive quarter of 2024 were 31, 44, 50, and 53, respectively, compared to 66, 62, 37, and 52 in each successive quarter of 2023, respectively. 27 Table of Contents Effect of Health-Related Outbreaks on Our Business Our global operations expose us to risks arising from public health crises and health-related outbreaks.
New design wins in each successive quarter of 2025 were 44, 53, 55, and 85, respectively, compared to 31, 44, 50, and 53 in each successive quarter of 2024, respectively.
The change was primarily due to other income of $6.1 million recognized from a strategic award received by the Company to develop a long-term plan to provide manufacturing services for aerospace and defense segments, a change in interest income earned on the money market cash account as a result of a change in cash balances, along with the non-recurrence of a loss on prepayment and termination of our 2019 Credit Facility, offset by non-recurrence of the employee retention tax credit of $2.0 million received during the second quarter of 2023.
Other income relates primarily to other income recognized from a strategic award we received to develop a long-term plan to provide manufacturing services for aerospace and defense segments. On July 4, 2025, the OBBBA was enacted.